Rhegen Bio

Shenzhen-based biotechnology company Rhegen Bio, specializing in mRNA technology, has reportedly raised RMB 100 million (USD 14.7 million) in a pre-Series B financing round. The funding was led by Fer-Capital Investment, with participation from Sequoia Capital China and other existing investors. The proceeds will be used to support clinical trials…